Journal List > Korean Circ J > v.41(3) > 1016660

Nam: Exercise, Heart and Health

Abstract

Regular physical activity provides a variety of health benefits, including improvement in cardiopulmonary or metabolic status, reduction of the risk of coronary artery disease or stroke, prevention of cancer, and decrease in total mortality. Exercise-related cardiac events are occasionally reported during highly competitive sports activity or vigorous exercises. However, the risk of sudden death is extremely low during vigorous exercise, and habitual vigorous exercise actually decreases the risk of sudden death during exercise. The cause of sudden death is ischemic in older subjects (≥35 years old), while cardiomyopathies or genetic ion channel diseases are important underlying pathology in younger (<35 years old) victims. The subgroup of patients who are particularly at higher risk of exercise-related sudden death may be identified in different ways, such as pre-participation history taking, physical examination and/or supplementary cardiac evaluation. Limitations exist because current diagnostic tools are not sufficient to predict a coronary artery plaque with potential risk of disruption and/or an acute thrombotic occlusion. Proper and cost-effective methods for identification of younger subjects with cardiac structural problems or genetic ion channel diseases are still controversial.

Introduction

The importance of exercise for maintenance of a healthy life is well appreciated. Regular physical activity offers a variety of health benefits not only in the general, healthy population, but also in subjects with cardiac diseases. This idea is supported by solid scientific evidence compiled over the past 50 years. The health benefits encompass all the aspects of life, from mere improvement in the physiologic functions, such as the cardiovascular/respiratory capacity and metabolic status, to achievement of hard end points, including reduction of the stroke and cancer risks, or even decrease in total mortality.1) In spite of this general positive effect of exercise, exercise-related cardiac events are not infrequently reported during highly competitive sports activity or vigorous exercises.2) In addition, certain groups of patients who have structural or genetic ion channel diseases are especially prone to develop life-threatening cardiac arrhythmias precipitated by vigorous physical exercise.3)4) This review describes the general health benefit of regular physical exercise, as well as the potential adverse effects of vigorous exercise; it also identifies the subgroup of patients who are at higher risk of exercise-related sudden death, and finally screening methods to avoid the potential hazard of exercise.

Benefits of Exercise

Health benefits of physical exercise

Prevention of coronary artery disease

Numerous epidemiologic studies have demonstrated a protective effect of exercise on coronary artery disease (CAD).5) A recent meta-analysis showed that a moderate-to-high level of leisure time physical activity was associated with a reduced risk of CAD. Specifically, vigorous and moderate exercise decreased the risk of CAD by 27% and 12%, respectively, compared with individuals with low or nil exercise activity.5) Possible contribution of exercise-induced blood pressure lowering, improved body composition, glucose tolerance, insulin sensitivity, and platelet function has been suggested.6)

Prevention of stroke

Studies on stroke prevention and meta-analysis of the studies7-10) indicated that moderate- to high-intensity exercise was associated with a reduced stroke risk. This protective effect is not only confined to ischemic stroke, but also extends to reduction of hemorrhagic and, therefore, the total stroke risk.7) Overall, moderately active individuals had a 20% lower risk and highly active individuals had a 27% lower risk of stroke incidence or mortality than the low-active individuals.8) Considering the pooled relative risk from studies on CAD and stroke prevention, the protective effect on stroke seemed comparable or even greater than the effect on CAD.7)
Hypertension is a risk factor for both ischemic and hemorrhagic strokes, and there is a direct dose-response relationship between blood pressure and stroke risk. Physical activity lowers blood pressure, improves lipid profiles, and also improves endothelial function, which enhances vasodilation and vasomotor function in the vessels. In addition, physical activity can play an antithrombotic role by reducing blood viscosity, fibrinogen levels, and platelet aggregability, all of which might reduce cardiac and cerebral events.8)

Prevention of cancers

There have been numerous epidemiologic studies on physical activity and cancer prevention.11) The available data indicate that physical activity has a different association with different types of cancers.11) Most studies focused on commonly occurring cancers (e.g., prostate, lung, colorectal for men, breast, lung, colorectal for women). The effect on the risk of colon cancer varied from 80% reduction to 60% increase. Overall, exercise was associated with a lower risk of colon cancer among both men and women. In addition, a dose-response relationship in cancer prevention was observed across levels of physical activity.11) In contrast, the available data show no clear association between physical activity and rectal cancer rates in men and women.11) It also appears that physically active women have a 20-30% reduced risk of breast cancer.12) Although exercise appears to be related with a lower risk of lung cancer, the confounding effect of smoking (passive smoking, depth of inhalation, use of filter tips etc) could not be completely controlled. There is no clear data supporting that physical activity decreases the risk of prostate cancer, with the median relative risk around 0.9. The data for other cancers, such as ovarian, testicular, pancreatic, kidney or bladder cancer, are limited. Although the beneficial effect of physical activity on the colon and breast cancers is obvious, the amount of exercise, the duration or frequency of exercise, as well as the dose-response relationship, is less clear.

Reduction of mortality

A significant relationship between physical activity and reduction in mortality has been reported, with a mortality reduction reaching up to 20-40%.13-16) A clear dose-response relationship was established and a larger volume of physical activity was related with a lower all-cause mortality.14)15) This inverse dose-response relationship has been shown both in men and women, in younger and older subjects.16) However, fewer data are available about the relationship between components of exercise dose (duration, intensity, frequency) and the improvement in longevity.15)

Other benefits

Other beneficial effects of exercise include modification of cardiovascular risk profiles, such as control of hypertension, improved lipid profile, prevention of type 2 diabetes, benefit on the bone-mineral metabolism and body composition.17)

Dose-response relationship

Earlier studies evaluating the role of exercise focused primarily on the beneficial effect of vigorous, sustained, aerobic exercise. Later, it became clear from epidemiology and controlled experiments that moderate intensity physical activity can also show substantial health benefits.17) Participation in physical activities above minimum recommended amounts provides additional health benefits in a dose-dependent manner. However, the point of maximum benefit for most health benefits has not been established, and may vary with many factors, such as age, sex, genetic or body composition.18) Even more, recent reports from the Women's Health Initiative or Women's Health Study confirmed that a physical activity of only one hour of walking per week may predict a significantly lower risk of CAD.19-21) An important quotation regarding the amount of exercise beneficial for health is "Even a little is good, more is better.", although this amount of activity might fall below the minimum requested in current guidelines.22)23)

Exercise Recommendation

Exercise recommendations from the 1970s prescribed continuous, vigorous exercise for 20 minutes, 3 days per week.24) Later consensus guideline recommended at least 30 minutes of accumulated, moderate-intensity activity per day, most days of the week.18) The updated recommendation specified that "All healthy adults aged 18-65 need moderate-intensity aerobic physical activity for a minimum of 30 minutes on five days each week or vigorous-intensity aerobic activity for a minimum of 20 minutes on three days each week".25)
A convenient way to estimate the energy expenditure during exercise is to calculate metabolic equivalents (METs) multiplied by exercise duration in minutes, where 1 MET corresponds to energy expenditure during sitted rest. The total, accumulated energy expenditure is the sum of the multiplication of METs of a specific physical activity and its duration. To meet the current recommendation, the minimum expenditure should be in the range of 450-750 MET×minutes per week.25) One may calculate the approximate requirement of physical activity by this multiplication of intensity and duration, and thus be able to combine different levels of exercise to meet the recommended dose of exercise. For example, if one walked briskly for 30 minutes three days a week (3 MET×30 minutes×3=270 MET×minutes), and played soccer for 30 minutes twice a week (8 MET×30 minutes×2=480 MET×minutes), the total energy expenditure would be 750 MET×minutes (Table 1).25)
Accumulation of shorter bouts of exercise (e.g., 10 minutes) towards the 30-minutes minimum can be as effective as single, longer bouts.25)26) Moreover, exercise may be compressed into fewer days of the week (e.g., exercise once or twice a week or on weekends only), with each activity session prolonged sufficiently enough to fall within current guidelines.21)25) The 2007 physical activity recommendations for healthy adults developed by the American Heart Association and the American College of Sports Medicine is summarized in Table 2.25)

Hazards of Exercise

Exercise and sudden cardiac death (Cardiovascular risk of vigorous exercise)

Regular physical activity substantially reduces the incidence of CAD and may improve survival. However, it has also been known that vigorous physical activity can precipitate acute myocardial infarction (AMI) or sudden cardiac death.2)27-29) A prospective study from the Veneto Region of Italy states that adolescents and young adults (<35 y.o.) engaged in competitive sports have an increased risk of SCD, compared with their non-athletic counterparts (the annual incidence of SCD was 2.3 in 100,000 in competitive athletes compared with 0.9 in non-athletes, with an estimated relative risk of 2.5).29) About 90% of all SCD were exercise-related in athletes, while only 9% of all SCD were related with exercise in the non-athletes group. It is generally accepted that sports, per se, is not a cause of increased mortality; rather, it acts as a trigger for cardiac arrest in the presence of underlying cardiovascular diseases predisposing to life-threatening ventricular arrhythmias.29)
For healthy adults, Thompson et al.30) reported 1 death per year for every 7,620 joggers, and Siscovick et al.2) estimated an annual rate of exercise-related cardiac arrest of 1 in 18,000 in previously healthy men.
The relative risk of SCD during vigorous exertion (marathon running) was significantly elevated at 16.9, compared with other situations.31) However, even with such intense physical efforts, the absolute risk for SCD was exceedingly small (1 per 1.51 million episodes of exertion, or 1 in 215,000 hours of running).31)32) In fact, the U.S. Physicians' Health Study, by comparing the relative risk of SCD according to the frequency of habitual vigorous exercise, demonstrated that habitual vigorous exercise diminishes the risk of sudden death during vigorous exertion.31) Precipitation of AMI follows a similar pattern. Although there is an increased risk of development of AMI with vigorous exercise, the risk is highest in individuals with low levels of habitual activity.27)33) Overall, the relative risk is lowest in the most physically active, while the relative risk is highest in sedentary individuals.

Cardiac pathology of exercise-related sudden cardiac death

It has been shown that acute cardiac events during exercise occur predominantly in individuals with structural heart diseases, and the distribution of cardiac diseases is dependent on ages. In individuals aged <35 years, cardiomyopathies or congenital heart diseases were responsible for the majority of the SCD victims, whereas CAD was the most frequent cause of death among older individuals (≥35 years).27)28)34-37) The different distribution of cardiovascular diseases between the two countries may be attributable to systematic pre-participation screening, leading to identification of athletes with hypertrophic cardiomyopathy (HCM) in Italian athletes (Table 3).

Mechanism of sudden cardiac death or ventricular fibrillation during sympathetic stimulation

Acute ischemia and sympathetic activation

CAD is the most common cause of SCD in older subjects. Even in previously asymptomatic adults, coronary artery plaque disruption (rupture or erosion) with acute thrombotic occlusion can be found. However, the mechanism by which vigorous exercise precipitates cardiac events is not clearly defined. Exercise-related physiologic changes, such as elevated blood pressure, increased heart rate, coronary artery spasm in the affected artery segment, may contribute to the plaque disruption. Other contributing factors include deepening of the coronary fissures, as well as catecholamine-induced platelet activation and aggregation. Once myocardial blood flow is severely impaired in acute ischemia, ATP-sensitive potassium channels open and, together with hyperkalemia or cellular acidosis, lead to a markedly increased dispersion of repolarization and cell-to-cell conduction, which ultimately leads to ventricular fibrillation (VF).38)

Congestive heart failure

The most prominent cellular electrophysiological alteration seen in failing heart is prolongation of the action potential duration. This is caused by down-regulation of the K+ currents and alteration in the inward Na+ and Ca++ currents. This action potential prolongation occurs inhomogeneously throughout the transmural myocardium, and serves as a substrate for reentrant ventricular tachyarrhythmias.39)40) In addition, altered channel gating property of the RyR receptor, reduced sarcoplasmic reticulum (SR) Ca++ ATPase function and increased Na-Ca exchange contribute to spontaneous Ca++ leak, decreased SR Ca++ contents, and reduced Ca++ transient. These changes, in association with up-regulated Na-Ca exchange and reduced inward rectifier K+ current, lead to contractile dysfunction and development of delayed afterdepolarization.41)42) Upon sympathetic stimulation, spontaneous Ca++ release and enhanced Na-Ca exchange, together with IK1 reduction, results in greater propensity for developing delayed after-depolarization.43)

Hypertrophic cardiomyopathy

In a large multicenter ICD registry, ventricular tachyarrhythmias appeared to play a major role in the pathogenesis of SCD in HCM, while bradyarrhythmia-mediated events could not be excluded as a cause of SCD.44) As sinus tachycardia was often the initiating rhythm before development of ventricular tachyarrhythmias, high sympathetic drive seemed to be proarrhythmic in patients with HCM.45)
It has been shown that the histological features of HCM are a markedly disorganized myocardial architecture, medial hypertrophy with luminal narrowing of the intramural coronary arteries, and replacement fibrosis after bursts of myocardial ischemia or myocyte necrosis.46) This highly heterogeneous substrate may be prone to develop ventricular tachyarrhythmias during exercise, due to outflow tract obstruction, myocardial ischemia or sympathetic surge, as previously demonstrated.47-49)

Arrhythmogenic right ventricular dysplasia

Arrhythmogenic right ventricular dysplasia (ARVD) is an inherited cardiomyopathy in which the right ventricular myocardium is progressively replaced by fat and fibrosis. SCD is frequently the first manifestation of the disease, and it occurs relatively frequently during exercise or stress. RV dilation, precordial repolarization abnormalities, and LV involvement have been associated with higher risk of sudden death.50)

Coronary artery anomaly

Congenital coronary artery anomaly indicates either the left main coronary artery arising from the right aortic sinus/pulmonary artery, or the right coronary artery arising from the left aortic sinus. Overall, it is an important cause of sudden death in young athletes. Cardiac events occur mainly during intense exertion probably provoked by myocardial ischemia from angulation of the coronary ostium or compression of the coronary artery. Premonitory symptoms (syncope, chest pain) may occur shortly before the onset of sudden death. Echocardiography or stress electrocardiogram (ECG) with maximal exercise may not disclose this anomaly, and a careful history taking revealing the presence of syncope or chest pain during exercise is crucial in the pre-participation screening of competitive athletes.51)

Myocardial bridge

Myocardial bridging is defined as a segment of a major epicardial coronary artery running intramurally through the myocardium, and is a common angiographic or autopsy finding. It is generally a benign congenital coronary artery anomaly, but it has been associated with angina, arrhythmia, depressed left ventricular (LV) function, myocardial stunning, and sudden death.52) Medical treatment with beta-blockers seems to be the first choice. However, intracoronary stents and surgery have been attempted in selected patients with refractory symptoms. Additional study is necessary to define the role of the myocardial bridge in the occurrence of sudden death, and to select the patients requiring invasive or surgical management.52)53)

Myocarditis

Myocarditis accounts for about 10% of the SCD in the young population. Infection or exposure to toxic chemicals/radiation can cause myocardial inflammation, and SCD results from conduction abnormalities or malignant ventricular tachyarrhythmias.50)

Mitral valve prolapse

The mitral valve prolapase (MVP) is a common echocardiographic abnormality, observed in about 3-4% of the general population. It is not a single disease entity, but a spectrum of different conditions, ranging from simple bowing of the mitral valve leaflet to redundant myxomatous leaflet and flail MV.54)55)
Although SCD frequently occurs during exercise, the MVP per se. may not be related with an increased risk of SCD. Instead, the risk of SCD is strongly associated with accompanying mitral regurgitation.54)55) The mechanism of SCD in patients with MVP is not clear. Ventricular tachyarrhythmias have been reported to occur more frequently in patients with MVP than in control subjects. However, this may be due to the presence of mitral regurgitation, not due to MVP itself. Therefore, the cause of SCD seems multifactorial, including ventricular tachyarrhythmias or atrioventricular block, hemodynamic dysfunction with severe hypotension, coronary artery spasm, hidden myocarditis or myocardial dysplasia.56)

The Wolff-Parkinson-White syndrome

The risk of SCD associated with ventricular preexcitation is less than 0.15% per year.57) The main mechanism of SCD seems to be atrial fibrillation conducting rapidly over an accessory pathway and degenerating into VF.58) Exercise is associated with an increased risk of VF. The approach to asymptomatic patients with ventricular preexcitation varies from simple observation to routine electrophysiological study and catheter ablation of the accessory pathway in patients with inducible atrial tachyarrhythmia.58) Considering the low risk of SCD in this aymptomatic population, the clinical decision should be individualized. Athletes with ventricular preexcitation should be evaluated for inducibility of supraventricular tachycardia and refractoriness of the accessory pathway before participation in competitive sports.69)

Long QT syndrome

It has been well demonstrated that subgroups of patients with long QT syndrome (LQTS) are sensitive to sympathetic stimulation. Arrhythmic events are often associated with physical exercise, emotional stress or auditory stimulation in long QT type 1 or 2.59) Swimming is a relatively genotype-specific arrhythmogenic trigger for both type 1 of the long QT syndrome and catecholaminergic polymorphic ventricular tachycardia (CPVT). In contrast, type 2 LQTS patients are susceptible to auditory stimulation or alarm.59)60)

Catecholaminergic polymorphic ventricular tachycardia

CPVT is an inherited disease characterized by a normal resting ECG, adrenergically-mediated bigemini premature ventricular contraction (PVC) and ventricular tachyarrhythmias. Mutation of the cardiac Ryanodine receptor 2 with impaired calcium-handling and delayed afterdepolarization was demonstrated to be the electrophysiological mechanism of fatal ventricular tachyarrhythmias.61)62)

Other genetic arrhythmia syndromes

Cardiac events in patients with short QT syndrome may occur during effort or loud noise, but this association appears to be weaker than in both LQTS and CPVT.63-65) The arrhythmogenic mechanism in patients with Brugada syndrome or early repolarization syndrome is strongly dependent on the vagal nerve activity, and exercise is less strictly prohibited compared with patients with LQTS, CPVT or HCM.66)

Exercise recommendations in patients with genetic cardiovascular diseases

Patients with Exercise recommendations in patients with genetic cardiovascular diseases (GCVDs) are at higher risk for SCD during exercise compared with normal subjects. The conflict between the known benefits and potential adverse outcomes of exercise requires careful weighing of the perceived risk to benefit ratio for each patient. It is generally recommended that patients with GCVDs can safely participate in most forms of recreational exercise of moderate or low intensity (i.e., equivalent to or lower than 6 METs). Activities requiring sudden acceleration or deceleration (burst exertion), exercise under extreme adverse environmental conditions, intense static exertion (weight lifting), exercises with potential risk of traumatic injury associated with loss of consciousness (free-weight lifting, rock climbing or ice hockey) or with possibilities of impaired consciousness during water-related activities are generally either not advised or strongly discouraged in all forms of genetic cardiovascular diseases.34)66) In addition, individual clinical judgment is required for patients with high risk clinical features, such as history of important cardiac symptoms, including syncope, prior cardiac operation, heart transplantation, presence of an implanted cardioverter-defibrillator or pacemaker, potentially life-threatening arrhythmias or other evidence of high-risk status.

Preparticipation screening

Due to the risk of exercise-related sudden death or other cardiac events, pre-participation screening for the susceptible subjects has emerged as an important issue in exercise recommendation. Brief guidelines for preparticipation are as follows.

Athletes

In Italy, a national pre-participation screening mandates annual evaluations that routinely include 12-lead ECG, in addition to medical history and physical examination. Wide implementation of the Italian screening model has been promoted by the endorsement of the European Society of Cardiology in 2005. Recent scientific evidence demonstrated this screening strategy to be useful for identification of HCM and other cardiomyopathies in asymptomatic athletes,67) and implementation of this program in Italy has been associated with substantial reduction in mortality due to cardiomyopathies.68) On the other hand, customary screening strategies for U.S. high school and college athletes is confined to medical history and physical examination at 2- to 4-year intervals.34) This is due to current lack of medical and financial resources, and more importantly, due to potentially deleterious effects to many athletes by virtue of false-positive test results that would lead to unnecessary further evaluation or disqualification.
To overcome this controversy, a new classification of the athlete ECG was proposed. ECG may be abnormal in up to 50% of athletes, which hinders the widespread use of ECG as part of the pre-participation screening. This new guideline classifies the changes seen on the athlete ECG into physiological (common and training-related) and pathological (uncommon and training-unrelated), to lower the traditionally high number of false-positive results and thus reducing unnecessary investigations69) (Table 4).

Non-athletes

Guidelines from the AHA indicated that exercise testing is not necessary for all people beginning a moderate intensity physical activity program. The rationale is based on the extremely low rate of cardiovascular complications in asymptomatic persons while performing moderate-intensity physical activity, on the poor predictive value of exercise testing for acute cardiac events and on the high costs of mass exercise testing. Symptomatic subjects or those suffering from any cardiovascular disease, diabetes, other active chronic disease, or with any medical concern in general, should consult a physician prior to any substantive increase in physical activity, particularly vigorous-intensity activity.25)

Other issues or adverse effects of exercise; the athletes' heart and commotio cordis

The athlete's heart

Exercise-related cardiac events occur predominantly in subjects with underlying structural abnormalities. However, exercise may cause a deleterious effect in individuals without underlying cardiac diseases. Athlete's heart denotes exercise-related electrical and structural remodeling. Intense resistance training increases LV wall thickness and mass with little or no change in the LV diameter, while aerobic exercise is associated with asymmetric LV hypertrophy.70)71)
Clinical implications of the athlete's heart include differential diagnosis from hypertrophic/dilated/RV cardiomyopathy, or possible long-term consequences of the extreme LV remodeling. As exercise itself causes alteration in the cardiac chamber size and morphology resembling those of cardiomyopathies, differential diagnosis of the athlete's heart (i.e., a physiological adaptation) from cardiomyopathies has long been a diagnostic dilemma. Athletes with benign right ventricular outflow tract VT may show wall motion abnormalities mimicking ARVD. In addition, concern has been raised that uninterrupted training per se, might ultimately cause irreversible cardiac dilatation,71) systolic dysfunction,72) or even ventricular tachyarrhythmias.73) A recent report, however, demonstrated that even young Olympic athletes exposed to extreme endurance training over long periods of time (up to 17 years) did not show deterioration in LV function and morphology or any occurrence of cardiovascular events. These findings confirmed the concept that the athlete's heart is a physiological adaptation to exercise, not causing irreversible cardiac remodeling.74)

Commotio cordis

Commotio cordis refers to VF and SCD triggered by a blunt, non-penetrating, and often innocent-appearing blow to the chest wall, without visible damage to the ribs, sternum, or heart, in individuals without previous structural heart diseases. It is an important cause of exercise-related SCD in young athletes, accounting for 3% of all sudden deaths in young, competitive athletes.75) A direct blow to the chest walls falling on a critical time of the cardiac cycle (i.e., 10-20 msec on the upstroke of the T wave) can precipitate VF. The cellular mechanism of VF initiation appears to be multifactorial. Instantaneous increase in the left ventricular intra-cavitary pressure and opening of stretch-activated ion channels, including ATP-sensitive potassium channels, may result in inhomogeneous repolarization of the myocardium, thus creating the vulnerable substrate for VF.76)

Conclusion

Regular physical activity provides a variety of health benefits, including improvement in the cardiopulmonary or metabolic status, reduction of the risk of CAD or stroke, prevention of cancer, and decrease in total mortality. These benefits offset the small but significant increase in the risk of SCD during vigorous exercise. There is a subgroup of patients, however, particularly at higher risk of sudden death during exercise. Proper identification of patients with hidden CADs, as well as screening of young subjects with structural or genetic ion channel diseases, may prove important for the prevention of exercise-related sudden death.

Figures and Tables

Table 1
Classification of physical activity according to the intensity of METs
kcj-41-113-i001

Modified from table 2, reference 25. METs: metabolic equivalents

Table 2
Physical activity recommendations for healthy adults aged 18-65 year
kcj-41-113-i002

Modified from table 4, reference 25

Table 3
Causes of sudden death in young adults
kcj-41-113-i003

Modified from references 28, 35. ARVC: arrhythmogenic right ventricular cardiomyopathy, AS: aortic stenosis, CA: coronary artery, CAD: coronary artery disease, CM: cardiomyopathy, CV: cardiovascular, HCM: hypertrophic cardiomyopathy, LAD: left anterior descending coronary artery, MVP: mitral valve prolapse, WPW: Wolff-Parkinson-White

Table 4
Classification of abnormalities seen on the electrocardiogram recorded in subjects with athlete's heart
kcj-41-113-i004

Adapted from references 69. ECG: electrocardiogram, RBBB: right bundle branch block, LBBB: left bundle branch block

Acknowledgments

This study was supported by a grant of the Korea Healthcare technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A100607).

Notes

The author has no financial conflicts of interest.

References

1. Blair SN, Morris JN. Healthy hearts and the universal benefits of being physically active: physical activity and health. Ann Epidemiol. 2009. 19:253–256.
2. Siscovick DS, Weiss NS, Fletcher RH, Lasky T. The incidence of primary cardiac arrest during vigorous exercise. N Engl J Med. 1984. 311:874–877.
3. Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation. 2009. 119:1085–1092.
4. Wever EF, Robles de Medina EO. Sudden death in patients without structural heart disease. J Am Coll Cardiol. 2004. 43:1137–1144.
5. Sofi F, Capalbo A, Cesari F, Abbate R, Gensini GF. Physical activity during leisure time and primary prevention of coronary heart disease: an updated meta-analysis of cohort studies. Eur J Cardiovasc Prev Rehabil. 2008. 15:247–257.
6. Sesso HD, Paffenbarger RS Jr, Lee IM. Physical activity and coronary heart disease in men: the Harvard Alumni Health Study. Circulation. 2000. 102:975–980.
7. Wendel-Vos GC, Schuit AJ, Feskens EJ, et al. Physical activity and stroke: a meta-analysis of observational data. Int J Epidemiol. 2004. 33:787–798.
8. Lee CD, Folsom AR, Blair SN. Physical activity and stroke risk: a meta-analysis. Stroke. 2003. 34:2475–2481.
9. Lee IM, Paffenbarger RS Jr. Physical activity and stroke incidence: the Harvard Alumni Health Study. Stroke. 1998. 29:2049–2054.
10. Lee IM, Hennekens CH, Berger K, Buring JE, Manson JE. Exercise and risk of stroke in male physicians. Stroke. 1999. 30:1–6.
11. Lee IM. Physical activity and cancer prevention: data from epidemiologic studies. Med Sci Sports Exerc. 2003. 35:1823–1827.
12. Lee IM, Cook NR, Rexrode KM, Buring JE. Lifetime physical activity and risk of breast cancer. Br J Cancer. 2001. 85:962–965.
13. Oguma Y, Sesso HD, Paffenbarger RS Jr, Lee IM. Physical activity and all cause mortality in women: a review of the evidence. Br J Sports Med. 2002. 36:162–172.
14. Lee IM, Hsieh CC, Paffenbarger RS Jr. Exercise intensity and longevity in men. The Harvard Alumni Health Study. JAMA. 1995. 273:1179–1184.
15. Lee IM, Skerrett PJ. Physical activity and all-cause mortality: what is the dose-response relation? Med Sci Sports Exerc. 2001. 33:6 Suppl. S459–S471.
16. Vogel T, Brechat PH, Leprětre PM, Kaltenbach G, Berthel M, Lonsdorfer J. Health benefits of physical activity in older patients: a review. Int J Clin Pract. 2009. 63:303–320.
17. Blair SN, Morris JN. Healthy hearts and the universal benefits of being physically active: physical activity and health. Ann Epidemiol. 2009. 19:253–256.
18. Pate RR, Pratt M, Blair SN, et al. Physical activity and public health: a recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA. 1995. 273:402–407.
19. Lee IM. Dose-response relation between physical activity and fitness: even a little is good; more is better. JAMA. 2007. 297:2137–2139.
20. Manson JE, Greenland P, LaCroix AZ, et al. Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med. 2002. 347:716–725.
21. Lee IM, Sesso HD, Oguma Y, et al. The "weekend warrior" and risk of mortality. Am J Epidemiol. 2004. 160:636–641.
22. Lee IM. Physical activity in women: how much is good enough? JAMA. 2003. 290:1377–1379.
23. Church TS, Earnest CP, Skinner JS, Blair SN. Effects of different doses of physical activity on cardiorespiratory fitness among sedentary, overweight or obese postmenopausal women with elevated blood pressure: a randomized controlled trial. JAMA. 2007. 297:2081–2091.
24. American College of Sports Medicine position statement on the recommended quantity and quality of exercise for developing and maintaining fitness in healthy adults. Med Sci Sports. 1978. 10:vii–x.
25. Haskell WL, Lee IM, Pate RR, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Circulation. 2007. 116:1081–1093.
26. Lee IM, Sesso HD, Paffenbarger RS Jr. Physical activity and coronary heart disease risk in men: does the duration of exercise episodes predict risk? Circulation. 2000. 102:981–986.
27. Thompson PD, Franklin BA, Balady GJ, et al. Exercise and acute cardiovascular events placing the risks into perspective: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism and the Council on Clinical Cardiology. Circulation. 2007. 115:2358–2368.
28. Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation. 2009. 119:1085–1092.
29. Corrado D, Basso C, Rizzoli G, Schiavon M, Thiene G. Does sports activity enhance the risk of sudden death in adolescents and young adults? J Am Coll Cardiol. 2003. 42:1959–1963.
30. Thompson PD, Funk EJ, Carleton RA, Sturner WQ. Incidence of death during jogging in Rhode Island from 1975 through 1980. JAMA. 1982. 247:2535–2538.
31. Albert CM, Mittleman MA, Chae CU, Lee IM, Hennekens CH, Manson JE. Triggering of sudden death from cardiac causes by vigorous exertion. N Engl J Med. 2000. 343:1355–1361.
32. Maron BJ, Poliac LC, Roberts WO. Risk for sudden cardiac death associated with marathon running. J Am Coll Cardiol. 1996. 28:428–431.
33. Siscovick DS, Ekelund LG, Johnson JL, Truong Y, Adler A. Sensitivity of exercise electrocardiography for acute cardiac events during moderate and strenuous physical activity: the lipid research clinics coronary primary prevention trial. Arch Intern Med. 1991. 151:325–330.
34. Maron BJ, Thompson PD, Ackerman MJ, et al. Recommendations and considerations related to pre-participation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation. 2007. 115:1643–1455.
35. Corrado D, Basso C, Schiavon M, Thiene G. Screening for hypertrophic cardiomyopathy in young athletes. N Engl J Med. 1998. 339:364–369.
36. Corrado D, Basso C, Thiene G. Sudden cardiac death in young people with apparently normal heart. Cardiovasc Res. 2001. 50:399–408.
37. Corrado D, Basso C, Pavei A, Michieli P, Schiavon M, Thiene G. Trends in sudden cardiovascular death in young competitive athletes after implementation of a pre-participation screening program. JAMA. 2006. 296:1593–1601.
38. Luqman N, Sung RJ, Wang CL, Kuo CT. Myocardial ischemia and ventricular fibrillation: pathophysiology and clinical implications. Int J Cardiol. 2007. 119:283–290.
39. Aiba T, Tomaselli GF. Electrical remodeling in the failing heart. Curr Opin Cardiol. 2010. 25:29–36.
40. Akar FG, Yan GX, Antzelevitch C, Rosenbaum DS. Unique topographical distribution of M cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome. Circulation. 2002. 105:1247–1253.
41. Yano M, Ono K, Ohkusa T, et al. Altered stoichiometry of FKBP12.6 versus ryanodine receptor as a cause of abnormal Ca(2+) leak through ryanodine receptor in heart failure. Circulation. 2000. 102:2131–2136.
42. Yano M, Yamamoto T, Kobayashi S, Ikeda Y, Matsuzaki M. Defective Ca2+ cycling as a key pathogenic mechanism of heart failure. Circ J. 2008. 72:Suppl A. A22–A30.
43. Pogwizd SM, Schlotthauer K, Li L, Yuan W, Bers DM. Arrhythmogenesis and contractile dysfunction in heart failure: roles of sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness. Circ Res. 2001. 88:1159–1167.
44. Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007. 298:405–412.
45. Cha YM, Gersh BJ, Maron BJ, et al. Electrophysiologic manifestations of ventricular tachyarrhythmias provoking appropriate defibrillator interventions in high-risk patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2007. 18:483–487.
46. Maron BJ. Hypertrophic cardiomyopathy. Lancet. 1997. 350:127–133.
47. Nicod P, Polikar R, Peterson KL. Hypertrophic cardiomyopathy and sudden death. N Engl J Med. 1988. 318:1255–1257.
48. McKenna WJ, Firoozi S, Sharma S. Arrhythmias and sudden death in hypertrophic cardiomyopathy. Card Electrophysiol Rev. 2002. 6:26–31.
49. Ly HQ, Greiss I, Talakic M, et al. Sudden death and hypertrophic cardiomyopathy: a review. Can J Cardiol. 2005. 21:441–448.
50. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006. 114:e385–e484.
51. Basso C, Maron BJ, Corrado D, Thiene G. Clinical profile of congenital coronary artery anomalies with origin from the wrong aortic sinus leading to sudden death in young competitive athletes. J Am Coll Cardiol. 2000. 35:1493–1501.
52. Barcin C, Kursaklioglu H, Kose S, Amasyali B. Coronary myocardial bridge constitutes a risk: but how to manage it? Int J Cardiol. 2010. 138:215–216.
53. Alegria JR, Herrmann J, Holmes DR Jr, Lerman A, Rihal CS. Myocardial bridging. Eur Heart J. 2005. 26:1159–1168.
54. Plicht B, Rechenberg W, Kahlert P, Buck T, Erbel R. Mitral valve prolapse: identification of high-risk patients and therapeutic management. Herz. 2006. 31:14–21.
55. Hayek E, Gring CN, Griffin BP. Mitral valve prolapse. Lancet. 2005. 365:507–518.
56. Alliot E, Clementy J, Prystowsky E. Fighting sudden cardiac death: a worldwide challenge. 2000. 1st ed. New York: Futura Publishing Co.
57. Munger TM, Packer DL, Hammill SC, Feldman BJ, Bailey KR, Ballard DJ, Holmes DR Jr, Gersh BJ. A population study of the natural history of Wolff-Parkinson-White syndrome in Olmsted County, Minnesota, 1953-1989. Circulation. 1993. 87:866–873.
58. Pappone C, Manguso F, Santinelli R, et al. Radiofrequency ablation in children with asymptomatic Wolff-Parkinson-White syndrome. N Engl J Med. 2004. 351:1197–1205.
59. Wilde AA, Roden DM. Predicting the long-QT genotype from clinical data: from sense to science. Circulation. 2000. 102:2796–2798.
60. Shimizu W, Antzelevitch C. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. J Am Coll Cardiol. 2000. 35:778–786.
61. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002. 106:69–74.
62. Liu N, Colombi B, Memmi M, et al. Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model. Circ Res. 2006. 99:292–298.
63. Gaita F, Giustetto C, Bianchi F, et al. Short QT Syndrome: a familial cause of sudden death. Circulation. 2003. 108:965–970.
64. Maury P, Extramiana F, Sbragia P, et al. Short QT syndrome: update on a recent entity. Arch Cardiovasc Dis. 2008. 101:779–786.
65. Giustetto C, Di Monte F, Wolpert C, et al. Short QT syndrome: clinical findings and diagnostic-therapeutic implications. Eur Heart J. 2006. 27:2440–2447.
66. Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation. 2004. 109:2807–2816.
67. Pelliccia A, Di Paolo FM, Corrado D, et al. Evidence for efficacy of the Italian national pre-participation screening programme for identification of hypertrophic cardiomyopathy in competitive athletes. Eur Heart J. 2006. 27:2196–2200.
68. Corrado D, Basso C, Pavei A, Michieli P, Schiavon M, Thiene G. Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program. JAMA. 2006. 296:1593–1601.
69. Corrado D, Pelliccia A, Heidbuchel H, et al. Recommendations for interpretation of 12-lead electrocardiogram in the athlete. Eur Heart J. 2010. 31:243–259.
70. Maron BJ, Pelliccia A. The heart of trained athletes: cardiac remodeling and the risks of sports, including sudden death. Circulation. 2006. 114:1633–1644.
71. Pelliccia A, Maron BJ, De Luca R, Di Paolo FM, Spataro A, Culasso F. Remodeling of left ventricular hypertrophy in elite athletes after long-term deconditioning. Circulation. 2002. 105:944–949.
72. Nishimura T, Yamada Y, Kawai C. Echocardiographic evaluation of long-term effects of exercise on left ventricular hypertrophy and function in professional bicyclists. Circulation. 1980. 61:832–840.
73. Ector J, Ganame J, van der Merwe N, et al. Reduced right ventricular ejection fraction in endurance athletes presenting with ventricular arrhythmias: a quantitative angiographic assessment. Eur Heart J. 2007. 28:345–353.
74. Pelliccia A, Kinoshita N, Pisicchio C, et al. Long-term clinical consequences of intense, uninterrupted endurance training in Olympic athletes. J Am Coll Cardiol. 2010. 55:1619–1625.
75. Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation. 2009. 119:1085–1092.
76. Maron BJ, Estes NA 3rd. Commotio cordis. N Engl J Med. 2010. 362:917–927.
TOOLS
Similar articles